Back to News
Market Impact: 0.2
XORT Targets FDA IND Filing For XRx-026 Gout Program; NDA Submission Planned Within A Year
Source: Nasdaq
Healthcare & BiotechRegulation & Legislation
XORTX Therapeutics plans to submit an Investigational New Drug application to the U.S. FDA in Q4 2026 for its late-stage gout and kidney-disease programs. The planned regulatory filing marks a positive development milestone, though the long timeline and absence of clinical data limit near-term valuation impact.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.20
Ticker Sentiment
XRTX0.35
More News
- Google's Gemini becomes latest AI model to break out and hack computer systems
- After threatening to seize Greenland by force, Trump agrees to leave it with Denmark and boost military presence. ‘We will be very protective of it!’
- Google’s Gemini AI hacks 3 companies in security test, then stops
- Analysis-Russia sanctions bill gives Trump sweeping new tariff powers
- India forces caller-ID apps to feed spam reports to telcos
- Anthropic selects Accenture as first embedded evaluator to help implement Amodei's slowdown proposal